Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions.

Date publication

août 2020

Journal

Cells, tissues, organs

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DALSTEIN Véronique , Pr POLETTE Myriam , Dr NAWROCKI-RABY Béatrice

Tous les auteurs :
Ancel J, Dewolf M, Deslée G, Nawrocky-Raby B, Dalstein V, Gilles C, Polette M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32750701

Résumé

Lung cancer is one of the most common solid cancers and represents the leading cause of cancer death worldwide. Over the last decade, research on the epithelial-mesenchymal transition (EMT) in lung cancer has gained increasing attention. Here, we review clinical and histological features of non-small-cell lung cancer associated with EMT. We then aimed to establish potential clinical implications of EMT in current therapeutic options, including surgery, radiation, targeted therapy against oncogenic drivers, and immunotherapy.

Mots clés

Epithelial-mesenchymal transition, Non-small-cell lung cancer, Resistance, Therapy

Référence

Cells Tissues Organs (Print). 2020 Aug 4;:1-19